Therapeutic Asset Ratings

147 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Entrectinib Central Nervous System Neoplasm	Hoffmann-La Roche	P1/2	CC (47)
Entrectinib Colorectal Cancer	Hoffmann-La Roche	P2	CC (46)
Entrectinib Pancreatic Neoplasm	Hoffmann-La Roche	P2	CC (46)
Giredestrant Ovarian Cancer	Hoffmann-La Roche	P2	CC (46)
Inavolisib Ovarian Cancer	Hoffmann-La Roche	P2	CC (46)
ro7247669 Breast Cancer	Hoffmann-La Roche	P2	CC (46)
Spk-10001 Huntington Disease	Hoffmann-La Roche	P1/2	CC (45)
ro7616789 Neuroendocrine Carcinoma	Hoffmann-La Roche	P1	CC (44)
Tocilizumab Neuroendocrine Carcinoma	Hoffmann-La Roche	P1	CC (44)
immunoglobulin G1-kappa, anti-[Homo sapiens MSTN (myostatin, growth differentiation factor 8, GDF8, GDF-8) latent myostatin complex], humanized monoclonal antibody; Type 2 Diabetes Mellitus	Hoffmann-La Roche	P1	CC (43)
rg6496 Huntington Disease	Hoffmann-La Roche	P1	CC (43)
RO7567132 Neoplasm	Hoffmann-La Roche	P1	CC (43)
ro7790121 Metabolic Dysfunction-Associated Steatohepatitis	Hoffmann-La Roche	P1	CC (43)
Empagliflozin Breast Cancer	Hoffmann-La Roche	P1/2	CC (43)
Englumafusp Alfa Non-Hodgkin Lymphoma	Hoffmann-La Roche	P1/2	CC (43)
ro7247669 Esophageal Squamous Cell Carcinoma	Hoffmann-La Roche	P1/2	CC (43)
ro7247669 Metastatic Melanoma	Hoffmann-La Roche	P1/2	CC (43)
Selicrelumab Breast Cancer	Hoffmann-La Roche	P1/2	CC (43)
Spk-8011Qq Hemophilia A	Hoffmann-La Roche	P1/2	CC (43)
ro7795081 Healthy Volunteers	Hoffmann-La Roche	P1	CC (41)
Phesgo / / 20,000 Unt In HER2-positive Breast Cancer	Hoffmann-La Roche	P1/2	CC (41)
ro7247669 Neoplasm	Hoffmann-La Roche	P1/2	CC (41)
LISPRO-PH20 COMPONENT RHUPH20 Multiple Sclerosis	Hoffmann-La Roche	P1	CC (40)
ro7428731 Glioblastoma	Hoffmann-La Roche	P1	CC (40)
ro7616789 Small Cell Lung Carcinoma	Hoffmann-La Roche	P1	CC (40)

Showing 101 to 125 of 147 assets

PreviousPage 5 of 6Next